Tempus AI’s stock has climbed 82.4% over the past 12 months, outpacing the broader healthcare technology sector and rewarding long‐term shareholders. This gain reflects sustained institutional interest, with average daily trading volume rising by more than 35% compared with the prior year, according to exchange data. Analysts have revised full‐year revenue forecasts upward by an average of 18% since January, signaling growing confidence in the company’s growth trajectory.

The company’s Genomics revenue segment reported year‐over‐year growth exceeding 55%, driven by expanded test volume from over 450 hospitals and cancer centers. Data & Services revenue more than doubled sequentially, bolstered by new long‐term contracts for clinical decision support in oncology and infectious disease. Tempus secured two additional FDA clearances in Q4—one for a novel RNA‐based companion diagnostic and another for a software platform supporting biomarker‐driven treatment selection.

Tempus achieved positive adjusted EBITDA for the first time in Q4, reducing its operating loss by 70% compared with the same period last year. Cash runway now extends into late 2027, following a strategic $150 million convertible note issuance in September. Additionally, the company will present eight abstracts at the 2026 ASCO Gastrointestinal Cancers Symposium, highlighting real‐world evidence from over 10,000 GI cancer patients and validating its AI‐driven precision medicine offerings.